As IM treatment does not eliminate the CML LSCs, we next tested the effect of RXRA ligands alone and in combination with IM in purified primary CML CD34+ cells in-vitro, and the cell viability and colony-forming capacity were assessed. This evidence concerns the gene RXRA and chronic myelogenous leukemia, BCR-ABL1 positive.